bluebird bio Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Andrew Obenshain (47 yo)

1.83yrs

Tenure

US$9,258,002

Compensation

Mr. Andrew Obenshain serves as Chief Executive Officer at bluebird bio, Inc. since 2021 and serves as its Director since 2021 also its President. He served as President of Severe Genetic Diseases since Oct...


CEO Compensation Analysis

How has Andrew Obenshain's remuneration changed compared to bluebird bio's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a

-US$431m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$563m

Dec 31 2021US$9mUS$486k

-US$563m

Compensation vs Market: Andrew's total compensation ($USD9.26M) is above average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Insufficient data to compare Andrew's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Andrew Obenshain
President1.83yrsUS$9.26m0.057%
$ 355.9k
Thomas Klima
Chief Commercial Officer & COO0.25yrUS$2.42m0.033%
$ 208.2k
Christopher Krawtschuk
CFO, Principal Accounting Officer & Treasurerno datano datano data
Elizabeth Pingpank
Director of Corporate Communicationsno datano datano data
Sarah Alspach
Chief Communications Officerno datano datano data
Andrea Walton
Chief People Officer0.83yrno datano data
Liviu Niculescu
Senior Vice President of Global Medical Affairsno datano datano data
Melissa Bonner
Senior Vice President of Research0.75yrno datano data
Richard Colvin
Chief Medical Officer1.67yrsno data0.021%
$ 130.7k
Kasra Kasraian
Senior Vice President of Technical Development & Operationsno datano datano data
Scott Shoemaker
Senior Vice President of Quality1.83yrsno datano data
Jessica Whitten
VP & Global Controllerno datano data0.011%
$ 65.7k

1.3yrs

Average Tenure

47.5yo

Average Age

Experienced Management: BLUE's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Andrew Obenshain
President1.83yrsUS$9.26m0.057%
$ 355.9k
Philip Reilly
Member of Scientific Advisory Board11.67yrsno datano data
Philippe Leboulch
Co-Chair of Scientific Advisory Boardno datano datano data
Stephen Goff
Member of Scientific Advisory Board11.67yrsno datano data
Mark Vachon
Independent Chairman8.33yrsUS$289.42k0.012%
$ 74.4k
Mitchell Finer
Member of Scientific Advisory Board7.33yrsUS$1.57mno data
Malcolm Brenner
Member of Scientific Advisory Board11.67yrsno datano data
Christof von Kalle
Member of Scientific Advisory Board11.67yrsno datano data
John Agwunobi
Independent Director5.42yrsUS$271.97k0.015%
$ 94.5k
Nick Leschly
Director12.67yrsUS$7.40m0.52%
$ 3.2m
R. Humphries
Member of Scientific Advisory Board11.67yrsno datano data
Elisabeth Leiderman
Director1yrUS$296.65kno data

11.7yrs

Average Tenure

63yo

Average Age

Experienced Board: BLUE's board of directors are seasoned and experienced ( 11.7 years average tenure).